Extera company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Acquired | Acquired

About Extera

Extera is an importer and distributor of health products. The company's main brands are Medartis, Integra LifeSciences , Aesculap , Polyganics , Teknimed , Cartiva Inc and Orfit.

Extera Headquarter Location

Rua Estado de Israel, 519 Vila Clementino

Sao Paulo, 04022-001,


55 11 3624-7844

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Extera News

Medartis : provides update on Brazil investigation

Dec 9, 2019

0 Message : 09.12.2019 - Medartis Holding AG Medartis Holding AG / Key word(s): ForecastMedartis provides update on Brazil investigation09-Dec-2019 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 KRThe issuer is solely responsible for the content of this announcement.---------------------------------------------------------------------------Medartis Holding AGHochbergerstrasse 60ECH-4057 BaselPRESS RELEASEMedartis provides update on Brazil investigationBasel, Switzerland, 9 December 2019 - Medartis Holding AG (SIX: MED), aleading manufacturer and provider of medical devices for surgical fixationof bone fractures, today provided an update on the ongoing investigations byBrazilian authorities into possible price and commission agreements acrossthe industry, including at Medartis' former distributor Extera prior to itsacquisition by Medartis in 2017. As a result a provision of CHF 3.0 millionhas been created, which will have an estimated impact on the EBITDA marginof around -2.5 percentage points in the current year. Excluding thisprovision, Medartis is confirming its guidance for 2019.As disclosed in the last Annual Report, the authorities in Brazil launchedinvestigations - in the context of intensified anti-corruption efforts inthe healthcare sector - into companies including Extera, the former Medartisdistributor acquired in 2017 and its former owners due to possible tenderprice agreements in 2012. Medartis is withholding CHF 1.0 million ofoutstanding payments for the acquisition of Extera to be potentially offsetagainst the costs arising from this matter and is evaluating to seek furtherindemnification from the former owners of Extera. Medartis is cooperatingwith the authorities. Based on its most recent contacts with the relevantauthorities in Brazil responsible for the investigations, Medartis hasreassessed the probability and currently anticipates potential claims, legalcosts and other related expenses of CHF 3.0 million. Accordingly, acorresponding provision has been created. No payments or fines are due atthis time.The provision is expected to impact Medartis' EBITDA margin for 2019 byaround -2.5 percentage points. Excluding this impact, Medartis is confirmingthe outlook for the full year 2019 that it communicated in August 2019, withrevenue growth of 8-10% in local currencies and an EBITDA margin in linewith the first half of 2019.The operations and current performance of Medartis in Brazil are notaffected by the investigations. In a continuing economically challengingenvironment, Medartis expects to report a dynamic growth rate of over 25% inBrazil for the full year 2019.ContactPatrick ChristHead Corporate ServicesMedartis Holding AGPhone: +41 61 633 34 70patrick.christ@medartis.comAbout MedartisFounded in 1997 and headquartered in Basel, Switzerland, Medartis is one ofthe world's leading manufacturers and providers of medical devices forsurgical fixation of bone fractures for upper and lower extremities as wellas for the craniomaxillofacial region. Medartis employs over 600 individualsacross its 13 locations, with products offered in over 50 countriesglobally. Medartis is committed to providing surgeons and operating theaterpersonnel with the most innovative titanium implants and instruments as wellas best in class service. For more information, please visitwww.medartis.com.DisclaimerThis communication does not constitute an offer or invitation to subscribefor or purchase any securities of Medartis Holding AG. This publication maycontain certain forward-looking statements and assessments or intentionsconcerning the company and its business. Such statements involve certainrisks, uncertainties and other factors which could cause the actual results,financial condition, performance or achievements of the company to bematerially different from those expressed or implied by such statements.Readers should therefore not place reliance on these statements,particularly not in connection with any contract or investment decision. Thecompany disclaims any obligation to update these forward-looking statements,assessments or intentions. Further, neither the company nor any of itsdirectors, officers, employees, agents, counsel or advisers nor any otherperson makes any representation or warranty, express or implied, as to, andaccordingly no reliance should be placed on, the accuracy or completeness ofthe information contained herein or of the views given or implied.---------------------------------------------------------------------------End of ad hoc announcement---------------------------------------------------------------------------

  • Where is Extera's headquarters?

    Extera's headquarters is located at Rua Estado de Israel, 519, Sao Paulo.

  • What is Extera's latest funding round?

    Extera's latest funding round is Acquired.

  • Who are the investors of Extera?

    Investors of Extera include Medartis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.